Trial Profile

A phase IIa study of prolonged use of cannabidiol in the prevention of Graft versus Host Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cannabidiol (Primary)
Indications Graft-versus-host disease
Focus Therapeutic Use
Sponsors TALENT Biotech

Most Recent Events

20 Sep 2018 According to a Kalytera Therapeutics media release, Dr. Moshe Yeshurun, Kalytera's Chief Medical Officer, was the Principal Investigator for the study. The study was conducted conducted at the Institute of Hematology, Davidoff Center, Rabin Medical Center, Petah Tikva, Israel.
16 Feb 2017 Results published in a Kalytera Therapeutics media release.
03 Feb 2017 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com